EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model

Sue Harnan iD, Ben Kearns iD, Alison Scope iD, Laetitia Schmitt iD, Dina Jankovic iD, Jean Hamilton iD, Tushar Srivastava iD, Harry Hill iD, Chu Chang Ku iD, Shijie Ren iD, Claire Rothery iD, Laura Bojke iD und 2 weitere

Health Technology Assessment · 2024

DOI: 10.3310/yapl9347 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Health Technology Assessment, 2024. Verfasst von Sue Harnan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK. Hauptthemen laut MEDLINE: Ceftazidime, Azabicyclo Compounds, Anti-Bacterial Agents, Quality-Adjusted Life Years. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 179 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Technology Assessment programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To limit the use of antimicrobials without disincentivising the development of novel antimicrobials, there is interest in establishing innovative models that fund antimicrobials based on an evaluation of their value as opposed to the volumes used. The aim of this project was to evaluate the population-level health benefit of ceftazidime-avibactam in the NHS in England, for the treatment of severe aerobic Gram-negative bacterial infections when used within its licensed indications. The results were used to inform National Institute for Health and Care Excellence guidance in support of commercial discussions regarding contract value between the manufacturer and NHS England.

Methods

The health benefit of ceftazidime-avibactam was first derived for a series of high-value clinical scenarios. These represented uses that were expected to have a significant impact on patients’ mortality risks and health-related quality of life. Patient-level costs and health-related quality of life of ceftazidime-avibactam under various usage scenarios compared with alternative management strategies in the high-value clinical scenarios were quantified using decision modelling. Results were reported as incremental net health effects expressed in quality-adjusted life-years, which were scaled to 20-year population in quality-adjusted life-years using infection number forecasts based on data from Public Health England. The outcomes estimated for the high-value clinical scenarios were extrapolated to other expected uses for ceftazidime-avibactam.

Results

The clinical effectiveness of ceftazidime-avibactam relative to its comparators was estimated by synthesising evidence on susceptibility of the pathogens of interest to the antimicrobials in a network meta-analysis. In the base case, ceftazidime-avibactam was associated with a statistically significantly higher susceptibility relative to colistin (odds ratio 7.24, 95% credible interval 2.58 to 20.94). The remainder of the treatments were associated with lower susceptibility than colistin (odds ratio < 1). The results were sensitive to the definition of resistance and the studies included in the analysis. In the base case, patient-level benefit of ceftazidime-avibactam was between 0.08 and 0.16 quality-adjusted life-years, depending on the site of infection and the usage scenario. There was a high degree of uncertainty surrounding the benefits of ceftazidime-avibactam across all subgroups, and the results were sensitive to assumptions in the meta-analysis used to estimate susceptibility. There was substantial uncertainty in the number of infections that are suitable for treatment with ceftazidime-avibactam, so population-level results are presented for a range of scenarios for the current infection numbers, the expected increases in infections over time, and rates of emergence of resistance. The population-level benefit varied substantially across the scenarios, from 531 to 2342 quality-adjusted life-years over 20 years.

Conclusion

This work has provided quantitative estimates of the value of ceftazidime-avibactam within its areas of expected usage within the NHS.

Limitations

Given existing evidence, the estimates of the value of ceftazidime-avibactam are highly uncertain. Future work Future evaluations of antimicrobials would benefit from improvements to NHS data linkages, research to support appropriate synthesis of susceptibility studies, and application of routine data and decision modelling to assess enablement value. Study registration No registration of this study was undertaken. Funding This award was funded by the National Institute for Health and Care Research (NIHR) Policy Research Programme (NIHR award ref: NIHR135592), conducted through the Policy Research Unit in Economic Methods of Evaluation in Health and Social Care Interventions, PR-PRU-1217-20401, and is published in full in Health Technology Assessment ; Vol. 28, No. 73. See the NIHR Funding and Awards website for further award information.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimeAzabicyclo CompoundsAnti-Bacterial AgentsQuality-Adjusted Life YearsCost-Benefit AnalysisDrug CombinationsGram-Negative Bacterial InfectionsTechnology Assessment, BiomedicalHumansEnglandState MedicineQuality of LifeMaleFemale

Stichwörter der Autor:innen

ANTI-BACTERIAL AGENTSBACTERIALCEFTAZIDIME-AVIBACTAMCOLISTINCOST-EFFECTIVENESS ANALYSISDRUG RESISTANCEEXPERT TESTIMONYGRAM-NEGATIVE BACTERIAL INFECTIONSMICROBIAL SENSITIVITY TESTSNETWORK META-ANALYSISOXACILLINASEQUALITY-ADJUSTED LIFE-YEARSSYSTEMATIC REVIEW

Substanzen

CeftazidimeAzabicyclo Compoundsavibactam, ceftazidime drug combinationAnti-Bacterial AgentsDrug Combinations

Autor:innen und Institutionen

  • Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK.
  • Centre for Health Economics, University of York, York, UK.

ORCID-Profile: Sue Harnan, Ben Kearns, Alison Scope, Laetitia Schmitt, Dina Jankovic, Jean Hamilton, Tushar Srivastava, Harry Hill, Chu Chang Ku, Shijie Ren, Claire Rothery, Laura Bojke, Mark Sculpher, Beth Woods

Förderung

  • Health Technology Assessment programme

Zitieren

APA

Harnan, S., Kearns, B., Scope, A., Schmitt, L., Jankovic, D., Hamilton, J., Srivastava, T., Hill, H., Ku, C. C., Ren, S., Rothery, C., Bojke, L., Sculpher, M., & Woods, B. (2024). Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model. Health Technology Assessment. https://doi.org/10.3310/yapl9347

Vancouver

Harnan S, Kearns B, Scope A, Schmitt L, Jankovic D, Hamilton J, et al. Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model. Health Technology Assessment. 2024. doi:10.3310/yapl9347

BibTeX
@article{Harnan2024,
  author = {Harnan, Sue and Kearns, Ben and Scope, Alison and Schmitt, Laetitia and Jankovic, Dina and Hamilton, Jean and Srivastava, Tushar and Hill, Harry and Ku, Chu Chang and Ren, Shijie and Rothery, Claire and Bojke, Laura and Sculpher, Mark and Woods, Beth},
  title = {Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model},
  journal = {Health Technology Assessment},
  year = {2024},
  doi = {10.3310/yapl9347}
}
Kostenlos starten →